Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
VECTORMUNE® HVT-NDV + Rispens
EN
HVT-F/NDV
No
-
Person:Dr Alexis Henry Gaetan GouxPresident of CIBio,Rua Manuel Joaquim Filho, 303 Pulinia - SP Sao Paulo, Brazil 13140-000Sao Paulo,
, BrazilPhone: +551938337700,Fax:Email: alexisgoux@ceva.com,Website:Related OrganizationCeva Saude Animal Ltda (CEVA) ()Rua Manuel Joaquim Filho, 303 Pulinia - SP Sao Paulo, Brazil 13140-000Sao Paulo,
, BrazilPhone: +551938337700,Fax:Email: alexisgoux@ceva.com,Website:
Vectormune HVT-NDV & Rispens is vaccine against Newcastle disease (ND) and Marek's Disease (MD; Rispens). The vaccine contains modified Turkey Herpesvirus (Marek's disease vaccine; serotype 3), expressing fusion protein from Newcastle disease virus, and an attenuated strain of Gallid alphaherpesvirus 2 (Marek's Disease virus) serotype 1.
Kindly note that only the Turkey Herpesvirus was modified (the Marek's Disease Virus serotype 1 was not).
EN
Kindly note that only the Turkey Herpesvirus was modified (the Marek's Disease Virus serotype 1 was not).
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-105225-3 Organism Meleagrid alphaherpesvirus 1 (Turkey herpesvirus, Meleagrid herpesvirus 1)Viruses
-
BCH-ORGA-SCBD-48969-9 Organism Gallid alphaherpesvirus 2Viruses
Turkey Herpesvirus: wild-type; strain FC126
EN
p45/46PecF
EN
- Other (Cell transfection and recombination)
|
0.275 kb
|
|
0.273 kb
|
|
1.660 kb
|
|
0.326 kb
|
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-105090-4 Fusion protein gene | Avian orthoavulavirus 1 (Newcastle disease virus, NDV)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-105217-2 Beta-actin gene promoter | Gallus gallus (Chicken, CHICK)Promoter
-
BCH-GENE-SCBD-114748-3 SV40 poly-adenylation signal | Macaca mulatta polyomavirus 1 (SV40, Simian vacuolating virus 40, simian virus 40, Rhesus macaque polyomavirus)Terminator
-
BCH-GENE-SCBD-114749-2 CMV Early Enhancer | Human betaherpesvirus 5 (Human cytomegalovirus, HCMV, HHV-5)Enhancer
Genetic elements from p45/p46PecF introduced into Turkey Herpesvirus:
The recombinant virus contains an expression cassette located in the intergenic region between genes UL45 and UL46 Turkey Herpesvirus (HVT). The recombinant virus was created by transfecting chick embryo fibroblast cells with wild-type HVT strain FC126 and the plasmid vector p45/46PecF. During viral packaging, recombination of the genetic material occurred due to the homologous sequences of UL45 and UL46 flanking the expression cassette in the plasmid vector and recombinant viruses were produced.
During viral transcription, the Cytomegalovirus enhancer promotes strong transcription from the chicken (Gallus gallus) beta-actin promoter and transcribes the Newcastle disease virus fusion protein (Protein F) before terminating at the Macaca mulatta polyomavirus 1 poly-adenylation signal.
The recombinant virus is sufficient to create immunity to Newcastle disease virus and Merek's disease virus (Gallid alphaherpesvirus 2). A second attenuated strain of the virulent Merek's Disease virus has been included to convey broader immunity against Merek's disease virus.
Note:
The expression of Protein F was confirmed using Southern blotting.
EN
The recombinant virus contains an expression cassette located in the intergenic region between genes UL45 and UL46 Turkey Herpesvirus (HVT). The recombinant virus was created by transfecting chick embryo fibroblast cells with wild-type HVT strain FC126 and the plasmid vector p45/46PecF. During viral packaging, recombination of the genetic material occurred due to the homologous sequences of UL45 and UL46 flanking the expression cassette in the plasmid vector and recombinant viruses were produced.
During viral transcription, the Cytomegalovirus enhancer promotes strong transcription from the chicken (Gallus gallus) beta-actin promoter and transcribes the Newcastle disease virus fusion protein (Protein F) before terminating at the Macaca mulatta polyomavirus 1 poly-adenylation signal.
The recombinant virus is sufficient to create immunity to Newcastle disease virus and Merek's disease virus (Gallid alphaherpesvirus 2). A second attenuated strain of the virulent Merek's Disease virus has been included to convey broader immunity against Merek's disease virus.
Note:
The expression of Protein F was confirmed using Southern blotting.
EN
- Vaccine
EN
EN
- Vectormune® ND + Rispens [ English ]
- US 6,866,852 B2 Patent.pdf [ English ]
- Advancement in Vaccination Against Newcastle Disease - Recombinant HVT NDV.pdf [ English ]
| Record type | Field | Record(s) | |
|---|---|---|---|
| Living Modified Organism | Related LMO(s) | 1 | |
